Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 255.55B +4.4% |
| Revenue (ttm) | 55.37B +1.3% |
| Net Income | 15.55B +6.6% |
| EPS | 6.20 +8.0% |
| Shares Out | n/a |
| PE Ratio | 16.44 |
| Forward PE | 23.51 |
| Dividend | 2.86 (2.80%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 1,874 |
| Average Volume | 2,958 |
| Open | 103.20 |
| Previous Close | 102.00 |
| Day's Range | 102.40 - 103.60 |
| 52-Week Range | 65.50 - 103.80 |
| Beta | 0.30 |
| RSI | 64.44 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck posts new Enflonsia RSV data in infants
Vanguard Russell 1000 Index Fund Buys 9,096 Shares of Merck & Co Inc (MRK)
Vanguard Russell 1000 Index Fund Buys 9,096 Shares of Merck & Co Inc (MRK)
Merck (MRK) Reports Positive Phase 3 Results for ENFLONSIA in RSV Trial
Merck (MRK) Reports Positive Phase 3 Results for ENFLONSIA in RSV Trial
Merck (MRK) Shares Promising Results from Enflonsia's Phase 3 SMART Trial
Merck (MRK) Shares Promising Results from Enflonsia's Phase 3 SMART Trial
Merck reports positive phase 3 second-season RSV data for ENFLONSIA
Merck & Co., Inc.: Merck Announces Positive New Data for ENFLONSIA (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities Merck (NYSE: MRK), known as MSD ...
Merck Announces Positive New Data for ENFLONSIA (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the saf...
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons.
Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery
Merck & Co. Inc. (NYSE: MRK) on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence (AI) and advanced analytics in drug discovery. This partnership aims...
Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery
Merck & Co. Inc. (NYSE: MRK) on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence (AI) and advanced analytics in drug discovery.
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro ( amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced h...
Vanguard U.S. Multifactor ETF Buys 13,222 Shares of Merck & Co Inc (MRK)
Vanguard U.S. Multifactor ETF Buys 13,222 Shares of Merck & Co Inc (MRK)
Vanguard Russell 1000 Value Index Fund Buys 9,849 Shares of Merck & Co Inc (MRK)
Vanguard Russell 1000 Value Index Fund Buys 9,849 Shares of Merck & Co Inc (MRK)
Vanguard Global Wellesley Income Fund Buys 2,739 Shares of Merck & Co Inc (MRK)
Vanguard Global Wellesley Income Fund Buys 2,739 Shares of Merck & Co Inc (MRK)
Vanguard U.S. Value Factor ETF Buys 11,263 Shares of Merck & Co Inc (MRK)
Vanguard U.S. Value Factor ETF Buys 11,263 Shares of Merck & Co Inc (MRK)
Vanguard U.S. Minimum Volatility ETF Buys 3,820 Shares of Merck & Co Inc (MRK)
Vanguard U.S. Minimum Volatility ETF Buys 3,820 Shares of Merck & Co Inc (MRK)
Vanguard Global Wellington Fund Buys 55,978 Shares of Merck & Co Inc (MRK)
Vanguard Global Wellington Fund Buys 55,978 Shares of Merck & Co Inc (MRK)
Merck (MRK) Partners with Mayo Clinic to Boost AI-Driven Drug Development
Merck (MRK) Partners with Mayo Clinic to Boost AI-Driven Drug Development
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
RAHWAY, N.J., & ROCHESTER, Minn.--(BUSINESS WIRE)--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.
PhRMA CEO: The next chair of PhRMA will be Merck CEO Rob Davis
PhRMA CEO Stephen Ubl sits down with CNBC's Annika Kim Constantino to discuss PhRMA's launch of America Cures and the decision to bring in Merck CEO Rob Davis as the next Chair of the PhRMA board.
Merck (MRK) Gains Keytruda Approval from Health Canada for New Formulation
Merck (MRK) Gains Keytruda Approval from Health Canada for New Formulation
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 3,295 Shares of Merck & Co Inc (MRK)
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 3,295 Shares of Merck & Co Inc (MRK)
See Which Of The Latest 13F Filers Holds MRK
At Holdings Channel, we have reviewed the latest batch of the 108 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 34 of these fun...
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
Symmetry Panoramic Global Equity Fund Buys 316 Shares of Merck & Co Inc (MRK)
Symmetry Panoramic Global Equity Fund Buys 316 Shares of Merck & Co Inc (MRK)